Rothschild & Co Redburn lowers price target on Cooper Companies (COO)
Rothschild & Co Redburn lowered its price target on Cooper Companies, contributing to a 3.2% decline in the stock on April 29, 2026. Shares of the large medical device company traded at $61.09 during the session, down from yesterday's close of $63.09.
The analyst action followed Cooper Companies' underwhelming fiscal Q2 2025 earnings report, which saw management reduce full-year organic sales growth guidance. This guidance cut was attributed to softening demand in both contact lenses and fertility markets, despite the company reporting a revenue beat and raising its full-year revenue and earnings per share outlook.
The decline extended recent pressure on the stock, which had already seen shares hit a 52-week low range of $61.71-$61.76 earlier on April 29, 2026. The $61.09 price reached during the session was below this range. Analyst sentiment remains mixed, with recent cuts from firms including Citigroup, Rothschild, and a "sell" rating from Goldman Sachs.
Why Cooper's future sales outlook disappointed investors
Cooper Companies operates in the specialised medical device sector, primarily manufacturing and selling contact lenses for vision correction and products used in fertility treatments. Their business relies on providing essential healthcare solutions to optometrists, ophthalmologists, and fertility clinics, generating revenue from the ongoing demand for these medical products and services.
Today's 3.2% decline stemmed directly from management's decision to reduce its full-year organic sales growth guidance for fiscal 2025. This adjustment followed an otherwise positive fiscal Q2 2025 earnings report, which included a revenue beat and an increase in the full-year revenue and earnings per share outlook. However, the market focused on the lowered sales growth forecast, driven by softening demand in both the contact lens and fertility markets, indicating a potential slowdown in their core business areas.
This re-evaluation of future growth prospects immediately impacted the stock price. During the trading day, Cooper Companies' shares traded as low as $61.09, reflecting a 3.2% drop from yesterday's close of $63.09.
Think of it like a restaurant that announces it beat last quarter's sales targets and expects to make more profit this year, but then quietly reveals it expects fewer customers to walk through the door next year. Even with good current performance, the market sees that dip in future customer traffic as a more significant indicator of the business's health moving forward.
Cooper Companies (The)
The Cooper Companies, Inc. (COO) is a healthcare enterprise specialising in medical devices and related services. Its operations are divided into two principal segments: CooperVision and CooperSurgical. CooperVision focuses on the development, manufacture, and global distribution of contact lenses, offering a comprehensive range including spherical, toric, and multifocal options to address various vision correction needs such as astigmatism, presbyopia, and myopia across the Americas, Europe, the Middle East, Africa, and Asia Pacific. CooperSurgical is dedicated to women's and family healthcare, providing medical devices, fertility solutions, genomics, diagnostics, and contraception products to healthcare professionals and patients worldwide. This segment's offerings include surgical and office products like PARAGARD and uterine manipulators, alongside fertility consumables, equipment, and genetic testing services. The Cooper Companies, Inc. was established in 1958 and is headquartered in San Ramon, California.